CSWYY OTC
China Shineway Pharmaceutical Group Limited
1W: +13.1%
1M: +26.9%
3M: +11.6%
YTD: +11.6%
1Y: +11.6%
3Y: +26.6%
5Y: +20.1%
$21.49
+0.00 (+0.00%)
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Balance Sheet Trends
Total Assets
$10.8B
+7.4% ▲
5Y CAGR: +8.4%
Total Liabilities
$2.7B
+5.5% ▲
5Y CAGR: +13.9%
Shareholders Equity
$8.1B
+8.0% ▲
5Y CAGR: +6.8%
Cash & Investments
$7.6B
+16.6% ▲
5Y CAGR: +13.9%
Total Debt
$335M
-3.3% ▼
5Y CAGR: -3.1%
Net Debt
-$6.9B
-18.4% ▼
Assets vs Liabilities & Equity
Year-over-Year Growth
View Full Balance Sheet
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| — Assets — | |||||
| Cash | $4.2B | $5.0B | $5.9B | $6.1B | $7.2B |
| Short-Term Investments | $4M | $4M | $20M | $350M | $377M |
| Cash & ST Investments | $4.2B | $5.1B | $5.9B | $6.5B | $7.6B |
| Net Receivables | -$4M | $975M | $1.3B | $1.2B | $1.0B |
| Inventory | $588M | $658M | $898M | $813M | $692M |
| Other Current Assets | $825M | $1.0B | $68M | $0 | $47M |
| Total Current Assets | $5.7B | $6.8B | $8.2B | $8.6B | $9.3B |
| Property, Plant & Equip. | $1.3B | $1.2B | $1.2B | $1.2B | $1.2B |
| Goodwill & Intangibles | $232M | $213M | $199M | $189M | $182M |
| Long-Term Investments | $1.5B | $1.4B | $0 | $0 | $0 |
| Other Non-Current Assets | -$1.5B | -$1.4B | $0 | $0 | $0 |
| Total Non-Current Assets | $1.5B | $1.4B | $1.4B | $1.4B | $1.5B |
| Total Assets | $7.2B | $8.2B | $9.6B | $10.0B | $10.8B |
| — Liabilities — | |||||
| Accounts Payable | $229M | $309M | $485M | $403M | $340M |
| Short-Term Debt | $0 | $0 | $300M | $330M | $334M |
| Deferred Revenue | -$8M | -$7M | $0 | $0 | $222M |
| Other Current Liabilities | $117M | $973M | $1.2B | $102M | $1.6B |
| Total Current Liabilities | $1.1B | $1.7B | $2.4B | $2.4B | $2.5B |
| Long-Term Debt | $0 | $0 | $0 | $0 | $0 |
| Other Non-Current Liab. | $0 | $0 | $0 | $0 | $7 |
| Total Non-Current Liabilities | $204M | $184M | $106M | $125M | $205M |
| Total Liabilities | $1.3B | $1.8B | $2.5B | $2.6B | $2.7B |
| — Equity — | |||||
| Common Stock | $88M | $88M | $88M | $88M | $88M |
| Retained Earnings | $5.9B | $6.4B | $6.3B | $6.7B | $0 |
| Accumulated OCI | -$487M | -$495M | $0 | $0 | $0 |
| Total Stockholders Equity | $5.9B | $6.4B | $7.0B | $7.5B | $8.1B |
| Total Liabilities & Equity | $7.2B | $8.2B | $9.6B | $10.0B | $10.8B |
| — Key Metrics — | |||||
| Total Debt | $15M | $7M | $301M | $347M | $335M |
| Net Debt | -$4.2B | -$5.0B | -$5.6B | -$5.8B | -$6.9B |
| Total Investments | $1.5B | $4M | $20M | $350M | $377M |